(Alliance News) - MaxCyte Inc on Wednesday said it had signed a strategic platform licence with Lion TCR to promote the latter's T cell receptor-T cell pipeline.
MaxCyte is a Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics".
The company will partner with the Singapore-based biotechnology company, which advances TCR-T cell therapies for tumours and life-threatening viral infections.
MaxCyte claims that the joint venture will help to promote Lion's TCR-T cell therapies, while also "enhanc[ing] MaxCyte's presence in Asia". The partnership will also offer the possibility of expansion into American and European markets.
Under the terms of the deal, Lion will obtain worldwide non-exclusive rights to use MaxCyte's unique electroporation technology and its trademarked ExPERT research instrument portfolio. In exchange, MaxCyte will receive annual licence fees and programme-related revenue.
MaxCyte Chief Executive Officer Maher Masoud said: "Through this important partnership, we will be able to help provide the opportunity for patients in Asia (and ultimately patients worldwide) to benefit from these innovative MRNA-based TCR-T cell treatments and continue supporting the development of new therapies for patients with solid tumours".
Shares in MaxCyte were up 5.9% at 397.00 pence each in London on Wednesday afternoon.
By Hugh Cameron, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
MaxCyte (MXCT)